Free accessResearch articleFirst published online 2013-11
Efficacy and Safety of Tenectaplase versus Streptokinase in Treating ST-Elevation Myocardial Infarction Patients in Hong Kong: A Four-Year Retrospective Review in Queen Elizabeth Hospital
Data were lacking in comparing tenectaplase (TNK) and streptokinase (SK) in treating Chinese ST elevation myocardial infarction (STEMI) patients. We sought to compare these 2 types of thrombolytics in our locality.
Methods
We analysed 196 STEMI patients who received either TNK or SK in our hospital from 2007 to 2011. We compared the mortality and other outcomes of these 2 groups of patients.
Results
In-hospital mortality has no significant difference between the TNK and the SK groups (8.9% vs 5.3%, p=0.322). Door-to-needle time was shorter in the TNK group (31±10 vs 25±7, p<0.001). Hypotension after drug administration was more common in the SK group than in the TNK group (21.1% vs. 3.0%, p<0.001).
Conclusion
TNK is at least as safe as SK in treating STEMI patients, with the advantage of shorter door-to-needle time and less frequent hypotensive effect. (Hong Kong j.emerg.med. 2013;20:359-363)
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet1994; 343(8893): 311–32.
3.
KeeleyE.C., BouraJ.A., GrinesC.L.Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet2003; 361(9351): 13–20.
4.
AndersenH.R., NielsenT.T., RasmussenK., ThuesenL., KelbaekH., ThayssenP.A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction, N Engl J Med2003; 349(8): 733–42.
5.
Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet1986; 1(8478): 397–402.
6.
Assessment of the safety and efficacy of a New Thrombolytic Investigators, Van De WerfF., AdgeyJ., ArdissinoD., ArmstrongP.W., AylwardP.. Single bolus tenecteplase compared with front loaded alteplase in acute myocardial infarction: the ASSENT- 2 double blind randomized trial. Lancet1999; 354(9180): 716–22.
7.
A comparison of reteplase with alteplase for acute myocardial infarction.The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) investigators. N Engl J Med1997; 337(16): 1118–23.
8.
O'GaraP.T., KushnerF.G., AscheimD.D., CaseyD.E.Jr, ChungM.K., de LemosJ.A.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol2013; 61(4): 485–510.
9.
PintoD.S., KirtaneA.J., NallamothuB.K., MurphyS.A., CohenD.J., LahamR.J.Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation2006; 114(19): 2019–25.
10.
LiangF., HuD., WangH., LiuR., ShiX., GaoM.Efficacy and safety of single-bolus tenecteplase compared with front-loaded alteplase in Chinese patients with acute myocardial infarction. J Geriatr Cardiol2007; 4(3): 137–41.
11.
LamS., LeeS.W.I., ChanK., ChanM., HaiJ.J., TamF.A 10-year review of thrombolytic therapy in patients with ST-segment elevation myocardial infarction in a university hospital in Hong Kong - intracranial bleeding and other outcomes. J Am Coll Cardiol2012; 59(13 suppl): E461.
12.
BoersmaE., MaasA.C., DeckersJ.W., SimoonsM.L.Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet1996; 348(9030): 771–5.
13.
MilavetzJ.J., GiebelD.W., ChristianT.F., SchwartzR.S., HolmesD.R.Jr, GibbonsR.J.Time to therapy and salvage in myocardial infarction. J Am Coll Cardiol1998; 31(6): 1246–51.
14.
ChareonthaitaweeP., GibbonsR.J., RobertsR.S., ChristianT.F., BurnsR., YusufS.The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. For the CORE Investigators (Collaborative Organisation for RheothRx Evaluation). Heart2000; 84(2): 142–8.
15.
McNamaraR.L., HerrinJ., WangY., CurtisJ.P., BradleyE.H., MagidD.J.Impact of delay in door-to-needle time on mortality in patients with ST-segment elevation myocardial infarction. Am J Cardiol2007; 100(8): 1227–32.
16.
LewA.S., LarameeP., CercekB., ShahP.K., GanzW.The hypotensive effect of intravenous streptokinase in patients with acute myocardial infarction. Circulation1985; 72(6): 1321–6.
17.
TorresS., AlbuquerqueA., GomesL., PimentaA.Arterial blood pressure behavior during the administration of intravenous streptokinase, in patients with acute myocardial infarction. Rev Port Cardiol2001; 20 Suppl 5: V-147–52.
